US 5,096,830 AGrant
Preterm Labor and Membrane Rupture Test
Issue Date:1992-03-17
•14 Claims
Abstract
A method for determining increased risk of labor and fetal membrane rupture after week 20 of pregnancy comprises obtaining a secretion sample from the vaginal cavity; and determining the presence of a fetal restricted antigen in the sample. The sample can be removed from anywhere in the vaginal cavity, but is preferably removed from the posterior fornix or and/or cervical os. One fetal restricted antigen is fetal fibronectin. In one embodiment of this invention, the sample is contacted with an insoluble support to which anti-(fetal restricted antigen) antibody is adhered, and the fetal restricted antigen binding to the support is determined. Alternatively, the class of substances of which the fetal restricted antigen is a member is captured with a general binding antibody (such as anti-human fibronectin antibody), anti-(fetal restricted antigen) antibody (such as anti-fetal fibronectin antibody) is conjugated with the support, and binding with fetal restricted antigen is determined. Reagents and reagent kits are also included.
Metadata
Assignee
- Adeza Biomedical Corporation
Inventors
- Andrew E. Senyei
- Nelson N. H. Teng
Application Information
Application Number:US 2449692
Filing Date:1988-09-15
Priority Date:1987-11-17
Art Unit:182
Classifications
IPC:
G01N 3348
Field of Search:
4354367510;518;547;548;63;65;814
Patent Drawings
This patent does not have any drawings.
Description
This invention is further illustrated by the following specific, but non-limiting examples. Temperatures are given in degrees Centigrade and percents as weight percents unless otherwise specified. Examples which are constructively reduced to practice herein are presented in the present tense, and examples representing laboratory experiments previously reduced to practice are presented in the past tense.
EXAMPLE 1
Polyclonal Anti-(fetal fibronectin) Antibodies
Fetal fibronectin is purified from amniotic fluid as described by Engvall and Ruoslahti, Int.J.Cancer. 20:1-5 (1977).
The anti-(fetal fibronectin) antibodies are elicited in rabbits using the immunization techniques and schedules described in the literature, e.g., Stollar, Methods of Enzymology. 70:70 (1980), immunizing the rabbits with the fetal fibronectin antigen. The antiserum is screened in a solid phase assay similar to that used for monoclonal antibodies, e.g., as described by Lange et al, Clin.Exp.Immunol. 25:191 (1976) and Pisetsky et al, J.Immun.Methods 41:187 (1981).
The IgG fraction of the antisera is purified further by affinity chromatography using CNBr-Sepharose 4B (Pharmacia Fine Chemicals) to which has been coupled fetal fibronectin. The method used for coupling is that recommended by the gel manufacturer, AFFINITY CHROMATOGRAPHY. Pharmacia Fine Chemicals, pp 15-18.
The column is equilibrated with from 2 to 3 volumes of buffer (0.01 M PBS, pH 7.2), and the anti-(fetal fibronectin) antibody containing solution is then applied to the column. The absorbency of the eluate is monitored at 280 nm until protein no longer passes from the column. The column is then washed with 0.1 M glycine buffer, pH 2.5, to desorb the immunoaffinity bound anti-fetal fibronectin antibody. Peak protein fractions are collected, pooled and dialyzed against 0.01 M PBS, pH 7.2, for 24-36 hr at 4.degree. C. with multiple buffer changes.
If a higher purity is desired, the affinity purified IgG can be passed through an adult plasma fibronectin bound affinity column by the procedure described above to remove any antibodies which would cross-react with adult plasma fibronectins.
EXAMPLE 2
Monoclonal Anti-(fetal antigen) Antibody
Using the purified fetal fibronectin obtained by the procedure of Example 1, mouse monoclonal antibodies to the fetal fibronectin are obtained using standard procedures of Galfre and Milstein, Methods in Enzym. 73:1 (1981) and Matsurra, H. and Hakomori, S. et al (supra), using fetal fibronectin as the antigen for immunizing the mice. The monoclonal antibodies are screened using a modification of the techniques described in the literature, e.g., Lange et al, Clin.Exp.Immunol. 25:191 (1976) and Pisetsky et al, J.Immun.Methods. 41:187 (1981).
Mouse monoclonal antibody is purified from ascites fluid or from hybridoma culture supernatants using Protein-A coupled Sepharose-4B (Pharmacia Fine Chemicals) according to the procedure of Tijsson, PRACTICE AND THEORY OF ENZYME IMMUNOASSAYS. Elsevier Science Publishers, pp 105-107 (1985).
EXAMPLE 3
Polyclonal Antibody Coated Microtiter Plate
Rabbit anti-(fetal fibronectin) prepared and further purified to remove adult fibronectin cross-reactivity as described in Example 1 is diluted to 10 .mu.g/mL in 0.05 M carbonate buffer, pH 9.6. 100 .mu.L is dispersed into each well of of an IMMULON II microtiter plate (Dynatech). The plate is covered and incubated 4 hr at room temperature or 4.degree. C. overnight. The plate is washed 4 times with Wash Buffer (0.02 M Tris HCl, 0.015 M NaCl, 0.05% TWEEN-20), filling and emptying the wells completely with each use. The plate is then blocked by dispersing into each well 200 .mu.L of a blocking solution (0.01 M PBS, 1% BSA, 0.02% NaN.sub.3, pH 7.4) and incubating for 1 hr at room temperature. The wells are then washed 4 times with Wash Buffer, as described above. The plate is now ready for immunoassay of samples.
EXAMPLE 4
Monoclonal Anitbody Coated Micotiter Plate
Goat F(ab').sub.2 anti-mouse IgG antibody (Tago) was diluted to 10 .mu.g/mL in 0.05 M carbonate buffer, pH 9.6. 100 .mu.L was dispersed into each well of an IMMULON II microtiter plate (Dynatech). The plate was covered and incubated 4 hr at room temperature or 4.degree. C. overnight. The plate was washed 4 times with Wash Buffer as described in Example 3. The plate was then blocked by dispensing into each well the Blocking Solution as described in Example 3. Mouse monoclonal anti-fetal fibronectin ascites prepared as in Example 2 was diluted 1/5000 with 0.01 M PBS-1% BSA, pH 7.4. 100 .mu.L of the solution was dispensed into each well of the blocked microtiter plate. The wells were incubated, covered, for 2 hr at room temperature or overnight at 4.degree. C. The plate was then washed 4 times with Wash Buffer as described above, and was then ready for immunoassay of samples.
EXAMPLE 5
Enzyme Labeled Anti-(fetal fibronectin) Antibody
Anti-(fetal antigen) antibody prepared in accordance with the procedures of Example 1 or Example 2 is conjugated with alkaline phosphatase following the one-step glutaraldehyde procedure Avrameas, Immunochemistry. 6:43 (1969).
EXAMPLE 6
Sandwich Immunoassay
Positive and negative controls were included in the test. The positive control was amniotic fluid of know fetal fibronectin concentration, appropriately diluted to fall within the assay range (20 ng/mL to 5 .mu.g/mL for a monoclonal based assay). The negative control was sample diluent. The Assay Standard was amniotic fluid of known fibronectin concentration, serially diluted in sample diluent to provide a standard curve, ranging from 20 ng to 5.mu.g/mL.
The sample diluent was the anti-protease cocktail described in U.S. Pat. No. 4,914,889, the entire contents of which are hereby incorporated by reference. It protects fibronectin-containing samples from proteolytic degradation during transit and storage. The solution consisted of 0.05 M Tris-HCl, pH 7.4; 0.15 M NaCl, 0.02% NaN.sub.3, 1 % BSA, 500 Kallikrein Units/mL of aprotinin, 1nM phenylmethylsulfonyl fluoride (PMSF) and 5 mM EDTA.
Swab samples collected from either the cervix or posterior fornix were immersed in 0.75 mL of sample diluent in a collection vial. The swabs were removed from the solution for the assay, and the solution was centrifuged at 13,000 rpm for 5 min to remove particulate. The supernatant contained any fetal fibronectin which was in the swab.
A microtiter plate prepared as in Example 3 or 4 is used for the assay. 100 .mu.L of each standard, sample, positive and negative control were placed in separate wells and incubated 2 hr at room temperature. The plate was washed 4 times with Wash Buffer as described in Examples 3 and 4. 100 .mu.L of alkaline phosphatase-conjugated goat anti-(human fibronectin) prepared as in Example 5 was diluted 1/1000 in Conjugate Buffer (0.02 M Tris-HCl, pH 8, 0.3 M NaCl, 0.05% TWEEN 20, 5% BSA, 0.02% NaN.sub.3). 100 .mu.L was dispensed into each well and incubated for 2 hr at room temperature. The plate was washed 4 times as previously described. 4 mg/mL of p-nitrophenylphosphate (PNPP) was used as the substrate. This was diluted in 0.18 M 2-amino-2-methyl-1-propanol (AMP) buffer, pH 9.5 with 0.12 mM MgCl.sub.2. 100 .mu.L was dispensed into each well of the microtiter plate. After a 5 min incubation at room temperature, the reaction rate in milli-OD/min was read at 405 nm on a V-MAX.TM. kinetic microtiter plate reader (Molecular Devices).
A standard curve was constructed by correlating increasing reaction rate with increasing fibronectin concentration in the standards. Unknowns were calculated directly from the curve or by using a pre-set computer program (Molecular Devices).
Claims
We claim:
1. A method for determining signs and symptoms indicating risk of delivery comprising a) obtaining a secretion sample from the vaginal cavity or the cervical canal for a pregnant patient after week 20 of pregnancy; and b) determining the presence of fetal fibronectin in the sample, the presence of fetal fibronectin in the sample indicating risk of delivery.
2. The method of claim 1 wherein the sample is removed from the posterior fornix.
3. The method of claim 1 wherein the sample is obtained from the cervical os.
4. The method of claim 1 comprising the steps of a) contacting diluted sample with an anti-(fetal fibronectin) antibody for a time sufficient to permit antigen-antibody binding to occur; and b) determining the presence of said binding.
5. He method of claim 4 comprising the steps of a) contacting the sample with an insoluble support to which anti-(fetal fibronectin) antibody is adhered for a time sufficient to permit antigen-antibody binding to occur; b) contacting the insoluble support with an anti-fibronectin antibody for a time sufficient to permit antigen-antibody binding to occur; and c) determining the presence of anti-fibronectin antibody on the insoluble support.
6. The method of claim 5 wherein the anti-fibronectin antibody has a physically detectable label.
7. The method of claim 5 wherein the presence of anti-fibronectin antibody is determined by a) contacting the insoluble support with a labeled antibody which binds selectively with the anti-fibronectin antibody; and b) determining the presence of the label on the insoluble support.
8. He method of claim 1 comprising the steps of a) contacting the sample with an insoluble support to which anti-fibronectin antibody is adhered for a time sufficient to permit antigen-antibody binding to occur; b) contacting the insoluble support with an anti-(fetal fibronectin) antibody for a time sufficient to permit antigen-antibody binding to occur; and c) determining the presence of anti-(fetal fibronectin) antibody on the insoluble support.
9. The method of claim 8 wherein the anti-(fetal fibronectin) antibody has a physically detectable label.
10. The method of claim 8 wherein the presence of anti-(fetal fibronectin) antibody is determined by a) contacting the insoluble support with a labelled antibody which binds selectively with the anti-(fetal fibronectin) antibody; and b) determining the presence of the label on the insoluble support.
11. The method of claim 1 wherein said method determines labor.
12. The method of claim 1 wherein said method determines fetal membrane rupture.
13. The method of claim 1 wherein said pregnant patient is a preterm patient.
14. The method of claim 1 wherein said pregnant patient is a term patient.
Patent Citations (5)
Non-Patent Literature (45)
- Oellevich, M., J. Clin. Chem. Clin. Biochem., vol. 22(12), pp. 895-904 (1984).
- The New England Journal of Medicine: vol. 325, No. 10, 669-674 (1991) "Fetal Fibronectin in Cervical and Vaginal Secretions as a Predictor of Preterm Delivery", by Lockwood et al.
- Int. J. Caner: 27, 763-767 (1981) "Fibronectin from Human Germ-Cell Tumors Resembles Amniotic Fluid Fibronectin", by Ruoslahti et al.
- Gahl et al., Obstet. Gynecol. 60: 297-304 (1982).
- Koninckx et al., Br. J. Obstet. Gynaecol. 88: 607-610 (1981).
- Huber et al., Br. J. Obstet. Gynaecol. 90(12): 1183-1185 (1983).
- Phocas et al., Eur. J. Obstet. Gynecol. Reprod. Biol. 31: 133-141 (1989).
- Ali, E. et al., J. Biol. Chem. 256: 7671-7677 (1981).
- Anonymous, Ob/Gyn Topics 2: 5 (1987).
- Anonymous, Ob. Gyn. News (Dec. 31, 1987).
- Anunciado, A. et al., Am. J. Obstet. Gynecol. 156: 898-890 (1987).
- Atlay, R. et al., Amer. J. Obstet. Gynec. 108: 993-994 (1970).
- Azzarone, B. et al., Int. J. Cancer 38: 177-181 (1986).
- Bala, S. et al., Aust. NZ. J. Obstet. Gynecol. 26: 141-144 (1986).
- Barnea, E. et al., ".beta.-HCG and Other Chemical Parameters of Ectopic Pregnancy", Maryland: Aspen Publishers, Inc. (1986).
- Bartal, A. et al., JNCI 76: 415-419 (1986).
- Bell, S. Human Reproduction 1: 129-143 (1986).
- Bergeron, C. et al., Contemporary Ob/Gyn 55-66 (1987).
- Bhatia, R. et al., Am. J. Obstet. Gynecol. 157: 106-108 (1987).
- The Human Placenta, Boyd, J. et al., New York: MacMillan Press (1970).
- Bray, B., Biochem. J. 226: 811-815 (1985).
- Bulmer, J. et al., Placenta 6: 127-140 (1985).
- Butzow, R. et al., Human Reproduction 1: 287-289 (1986).
- Cossu, G. et al., J. Biol. Chem. 258: 5603-5607 (1983).
- Dodds, W. et al., J. Reprod. Med. 32: 527-530 (1987).
- Friedman, M. et al., Am. J. Obstet. Gynecol. 104: 544-550 (1969).
- Ganrot, P., Scand. J. Clin. Lab. Invest. 29: 83-88 (1972).
- Hayashi, M. et al., J. Biol. Chem. 256: 11292-11300 (1981).
- Hess, L., Obstet. Gynecol. 68: 25-28 (1986).
- Immunoassays for the 80s, Voller et al. (ed.), Baltimore: University Park Press (1981).
- Johnson, P. et al., J. Immunol. 132: 1608-1610 (1984).
- Kiyotoshi, S. et al., Biochem. Biophys. Res. Comm. 116: 534-540 (1983).
- Kuusela, P. et al., Scand. J. Immunol. 12: 331-337 (1980).
- Leveno, K. et al., "Dilemmas in the Management of Preterm Birth, Part One, Pregnancies at Risk", Williams Obstetrics Supplement, 12, May/Jun. 1987.
- Matsuura, J. et al., Proc. Natl. Acad. Sci. U.S.A. 82: 6517-6521 (1985).
- McCoshen, J., Contemporary Ob/Gyn May, 1987: 94-117.
- McSweeney, D. et al., Fertility and Sterility 18: 866-869 (1967).
- Murayama, K. et al., Gylcoconjugate 1: 155-169 (1984).
- Sandler, S. et al., S. A. Medical Journal Sep., 1977: 487-492.
- Sbarra, A. et al., Obstet. Gynecol. 70: 107-110 (1987).
- Sinosich, M. et al., Obstet. and Gynecol. Survey 40: 273-282 (1985).
- Stubbs, T. et al., Am. J. Obstet. Gynecol. 155: 829-834 (1986).
- Wagner, D. et al., J. Biol. Chem. 256: 11708-11715 (1981).
- Yuen, H., "Clinical Applications of the HCG-.beta. Subunit Assay in Obstetrics and Gynecology", Current Problems in Obstetrics, Gynecology and Fertility, Chicago: Year Book Medical Publishers, Inc., (Sep. 1985).
- Zhu, B. et al., J. Biol. Chem. 259: 3962-3970 (1984).